Severe outcomes from Respiratory Syncytial Virus (RSV) continue to pose a grave threat to the nation’s most vulnerable populations, especially babies and older adults. As infections typically peak during the fall and winter months, experts are calling for increased utilization of new preventive measures and a focused effort to address troubling racial and ethnic health disparities associated with the illness. A recent webinar hosted by the National Minority Quality Forum offers a crucial and timely conversation on this topic, featuring a diverse panel of experts who detail the disease, the science of protection, and strategies for equitable access.

The discussion, titled “A Safe Start for Every Baby: What Every Parent, Clinician, Hospital, and Payer Should Know About RSV,” immediately establishes the urgency of the threat. Dr. Yaba Beysolow, a pediatrician and immunization expert, explained that RSV is a common, highly contagious germ that can spread through cough or sneeze droplets, entering the body through the eyes, nose, or mouth. While adults often experience only mild cold symptoms, severe RSV can be deadly for infants and older adults. Video footage shared during the session powerfully illustrates the danger, showing babies struggling with fast, short breaths, grunting noises, and the chest caving in with each inhalation—symptoms that can lead to a dangerous lack of oxygen. The session also highlights concerning health equity data: studies revealed that RSV infection rates were significantly higher in Black and Hispanic children under five compared to white children, with rates rising two to three times higher in 2022. Viewers learn that ICU admission rates for Black infants under six months were almost one and a half times higher than for white infants, underscoring the urgent need for intentional protection strategies.

Crucially, the full session details the dual strategies now available to protect infants against this respiratory threat. Experts explain that protection can be achieved either by vaccinating the pregnant mother between 32 and 36 weeks’ gestation, allowing her to transfer protective antibodies to the baby, or by giving the baby ready-made protection through monoclonal antibodies, such as nirsevimab (Beyfortus). Dr. Beysolow confirmed that either the maternal vaccine or the baby’s shot is recommended, but advised against utilizing both. Beyond the clinical science, the panelists explore the challenging but successful efforts to implement these guidelines on the ground, sharing vital insights for community leaders and healthcare administrators. The team from New York City Health + Hospitals/Elmhurst, which serves a community speaking more than 160 languages, describes their comprehensive multi-touchpoint approach, ensuring that discussions of RSV prophylaxis are integrated into prenatal clinics, birth hospitalization, and first clinic visits to provide equitable access to care.

The necessity of community engagement in combating vaccine hesitancy and misinformation is also a cornerstone of the discussion. Jonathan Ferrell of the Faith Health Alliance provides a powerful account of how their organization leverages high-trust environments, such as the church, to deliver clear, visually engaging, and repeatable messaging about RSV to their predominantly Black congregation. Ferrell explains their strategy of moving congregation members from simple awareness to understanding and application over a four-week period, and how they created spaces for judgment-free questions to proactively dispel myths—such as the notion that RSV is “just a bad cold” or that only infants are affected.

To fully understand the clinical recommendations, learn how major health systems like Elmhurst achieved a 75 percent protection rate for newborns despite initial supply shortages, and grasp the effective community models for fighting misinformation, stakeholders are encouraged to view the entire video session. The experts provide actionable information on access, including coverage details for vaccines and immunizations through Medicaid and the Vaccines for Children (VFC) program. For anyone committed to ensuring a safe start for every baby and protecting vulnerable older adults, this comprehensive conversation offers authoritative guidance and essential strategies.